# Jhanelle E. Gray

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jhanelle-e-gray/

## Facts

| Field | Value |
| --- | --- |
| Citations | 34,479 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 54 |
| i10-index | 126 |
| Last Known Institution | Moffitt Cancer Center |
| OpenAlex ID | https://openalex.org/A5007121755 |
| ORCID iD | 0000-0003-1304-7062 |
| Works | 737 |

## Researcher papers

Showing 12 of 16.

- [Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-in-metastatic-non-small-cell-lung-cancer/)
- [Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/osimertinib-in-untreated-i-egfr-i-mutated-advanced-non-small-cell-lung-cancer/)
- [Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer](https://scholariq.org/papers/durvalumab-after-chemoradiotherapy-in-stage-iii-non-small-cell-lung-cancer/)
- [Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC](https://scholariq.org/papers/overall-survival-with-osimertinib-in-untreated-i-egfr-i-mutated-advanced-nsclc/)
- [Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC](https://scholariq.org/papers/overall-survival-with-durvalumab-after-chemoradiotherapy-in-stage-iii-nsclc/)
- [Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/updated-analysis-from-keynote-189-pembrolizumab-or-placebo-plus-pemetrexed-and/)
- [Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study](https://scholariq.org/papers/pembrolizumab-plus-pemetrexed-and-platinum-in-nonsquamous-non-small-cell-lung/)
- [Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial](https://scholariq.org/papers/four-year-survival-with-durvalumab-after-chemoradiotherapy-in-stage-iii-nsclc-an/)
- [Structure-based classification predicts drug response in EGFR-mutant NSCLC](https://scholariq.org/papers/structure-based-classification-predicts-drug-response-in-egfr-mutant-nsclc/)
- [Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma](https://scholariq.org/papers/differential-association-of-stk11-and-tp53-with-kras-mutation-associated-gene/)
- [Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC](https://scholariq.org/papers/three-year-overall-survival-with-durvalumab-after-chemoradiotherapy-in-stage-iii/)
- [Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in <i>EGFR</i> -Mutant NSCLC](https://scholariq.org/papers/landscape-of-egfr-dependent-and-independent-resistance-mechanisms-to-osimertinib/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)

## Researcher university

- [Moffitt Cancer Center](https://scholariq.org/institutions/moffitt-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.